These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

770 related items for PubMed ID: 10637835

  • 1. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
    Bongioanni P, Romano MR, Boccardi B, Lombardo F, Moscato G, Mosti S, Baldini C, Nuti S, Meucci G, Rossi B.
    Rev Neurol; ; 29(10):893-9. PubMed ID: 10637835
    [Abstract] [Full Text] [Related]

  • 2. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H, Feng-Jun M, Osoegawa M, Minohara M, Murai H, Taniwaki T, Kira J.
    J Neurol Sci; 2004 Jul 15; 222(1-2):65-73. PubMed ID: 15240198
    [Abstract] [Full Text] [Related]

  • 3. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
    Nicoletti F, Di Marco R, Patti F, Zaccone P, L'Episcopo MR, Reggio E, Xiang M, Nicoletti A, Reggio A.
    Cytokine; 2000 Jun 15; 12(6):682-7. PubMed ID: 10843745
    [Abstract] [Full Text] [Related]

  • 4. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, Weller M, Wiendl H.
    J Neuroimmunol; 2004 Oct 15; 155(1-2):172-82. PubMed ID: 15342209
    [Abstract] [Full Text] [Related]

  • 5. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.
    Mei FJ, Osoegawa M, Ochi H, Minohara M, Nan S, Murai H, Ishizu T, Taniwaki T, Kira J.
    J Neurol Sci; 2006 Jul 15; 246(1-2):71-7. PubMed ID: 16581087
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
    Perini P, Tiberio M, Sivieri S, Facchinetti A, Biasi G, Gallo P.
    Eur Cytokine Netw; 2000 Mar 15; 11(1):81-6. PubMed ID: 10705303
    [Abstract] [Full Text] [Related]

  • 7. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
    Weber F, Polak T, Günther A, Kubuschok B, Janovskaja J, Bitsch A, Poser S, Rieckmann P.
    Ann Neurol; 1998 Jul 15; 44(1):27-34. PubMed ID: 9667590
    [Abstract] [Full Text] [Related]

  • 8. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses.
    Scheurich P, Thoma B, Ucer U, Pfizenmaier K.
    J Immunol; 1987 Mar 15; 138(6):1786-90. PubMed ID: 3029221
    [Abstract] [Full Text] [Related]

  • 9. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha.
    Albanesi C, Cavani A, Girolomoni G.
    J Immunol; 1999 Jan 01; 162(1):494-502. PubMed ID: 9886425
    [Abstract] [Full Text] [Related]

  • 10. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
    Elsässer-Beile U, Kölble N, Grussenmeyer T, Wetterauer U, Schultze-Seemann W.
    Anticancer Res; 1998 Jan 01; 18(3B):1883-90. PubMed ID: 9677439
    [Abstract] [Full Text] [Related]

  • 11. Interferon (IFN)-gamma , tumor necrosis factor-alpha , interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis.
    Ansari NA, Ramesh V, Salotra P.
    J Infect Dis; 2006 Oct 01; 194(7):958-65. PubMed ID: 16960784
    [Abstract] [Full Text] [Related]

  • 12. Expression of TNF-alpha mRNA by peripheral blood mononuclear cells of multiple sclerosis patients treated with IFN-beta 1A.
    Sarchielli P, Critelli A, Greco L, Sokola E, Floridi A, Gallai V.
    Cytokine; 2001 Jun 07; 14(5):294-8. PubMed ID: 11444910
    [Abstract] [Full Text] [Related]

  • 13. Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis.
    Ysrraelit MC, Gaitán MI, Lopez AS, Correale J.
    Neurology; 2008 Dec 09; 71(24):1948-54. PubMed ID: 19064876
    [Abstract] [Full Text] [Related]

  • 14. Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis.
    Link J, Söderström M, Olsson T, Höjeberg B, Ljungdahl A, Link H.
    Ann Neurol; 1994 Sep 09; 36(3):379-86. PubMed ID: 8080246
    [Abstract] [Full Text] [Related]

  • 15. T cell lymphokine-induced secretion of cytokines by monocytes from patients with multiple sclerosis.
    Maimone D, Reder AT, Gregory S.
    Cell Immunol; 1993 Jan 09; 146(1):96-106. PubMed ID: 8425234
    [Abstract] [Full Text] [Related]

  • 16. Expansion of CD4+CD28- T cells producing high levels of interferon-{gamma} in peripheral blood of patients with multiple sclerosis.
    Miyazaki Y, Iwabuchi K, Kikuchi S, Fukazawa T, Niino M, Hirotani M, Sasaki H, Onoé K.
    Mult Scler; 2008 Sep 09; 14(8):1044-55. PubMed ID: 18573819
    [Abstract] [Full Text] [Related]

  • 17. The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis.
    Hedegaard CJ, Krakauer M, Bendtzen K, Sørensen PS, Sellebjerg F, Nielsen CH.
    Clin Immunol; 2008 Oct 09; 129(1):80-9. PubMed ID: 18653385
    [Abstract] [Full Text] [Related]

  • 18. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.
    Jensen J, Krakauer M, Sellebjerg F.
    Cytokine; 2005 Jan 07; 29(1):24-30. PubMed ID: 15579375
    [Abstract] [Full Text] [Related]

  • 19. Interferon-gamma and tumor necrosis factor-alpha induce synergistic cytolytic effects in ovarian cancer cell lines-roles of the TR60 and TR80 tumor necrosis factor receptors.
    Kost ER, Mutch DG, Herzog TJ.
    Gynecol Oncol; 1999 Mar 07; 72(3):392-401. PubMed ID: 10053112
    [Abstract] [Full Text] [Related]

  • 20. Impact of immunomodulatory treatment on leukocyte cytokine production in multiple sclerosis patients and healthy donors.
    Reske D, Thomas AV, Petereit HF, Fink GR, Schroeter M.
    Neuroimmunomodulation; 2009 Mar 07; 16(6):385-91. PubMed ID: 19609087
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.